PepGen (PEPG) to Release Earnings on Thursday

PepGen (NASDAQ:PEPG) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.05. On average, analysts expect PepGen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PepGen Price Performance

PEPG opened at $1.71 on Thursday. The company has a fifty day moving average price of $1.78 and a 200-day moving average price of $3.28. The firm has a market capitalization of $118.28 million, a P/E ratio of -0.98 and a beta of 1.88. PepGen has a one year low of $1.01 and a one year high of $7.80.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Wedbush reduced their target price on PepGen from $5.00 to $4.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a report on Sunday, June 7th. Craig Hallum began coverage on PepGen in a research report on Tuesday, June 16th. They set a “buy” rating and a $11.00 price target for the company. Weiss Ratings downgraded PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 2nd. Finally, HC Wainwright restated a “buy” rating on shares of PepGen in a research report on Thursday, May 21st. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Institutional Investors Weigh In On PepGen

A number of large investors have recently added to or reduced their stakes in PEPG. RA Capital Management L.P. lifted its stake in PepGen by 87.7% during the third quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock worth $92,698,000 after purchasing an additional 9,375,000 shares during the last quarter. Viking Global Investors LP increased its position in shares of PepGen by 134.9% during the 3rd quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock valued at $16,089,000 after purchasing an additional 2,000,000 shares during the last quarter. Vivo Capital LLC bought a new position in shares of PepGen during the 3rd quarter valued at about $10,742,000. Laurion Capital Management LP raised its holdings in shares of PepGen by 8.5% during the 4th quarter. Laurion Capital Management LP now owns 2,052,133 shares of the company’s stock valued at $13,359,000 after buying an additional 159,977 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of PepGen by 88.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,768,356 shares of the company’s stock valued at $8,170,000 after buying an additional 831,333 shares in the last quarter. Hedge funds and other institutional investors own 58.01% of the company’s stock.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).